A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.905490
Abstract: The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1… read more here.
Keywords: prognostic scoring; sf3b1 mutation; model; patients sf3b1 ... See more keywords